Together, these results indicate a putative RA/c-Raf/GSK-3/RARα axis that is susceptible to RRD-251 and represents a novel regulatory pathway for RA differentiation that may extend its utility beyond APL to other myeloid leukemias. This evidence concerns the gene RARA and acute promyelocytic leukemia.